Cargando…

Immune control in chronic myeloid leukemia

Detalles Bibliográficos
Autores principales:	Ilander, Mette, Mustjoki, Satu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5732686/ https://www.ncbi.nlm.nih.gov/pubmed/29262520 http://dx.doi.org/10.18632/oncotarget.22279

Ejemplares similares

IFNα induces prolonged remissions modeling curative immunologic responses in chronic myeloid leukemia
por: Ilander, Mette, et al.
Publicado: (2014)

Enlarged Memory T-Cell Pool and Enhanced Th1-Type Responses in Chronic Myeloid Leukemia Patients Who Have Successfully Discontinued IFN-α Monotherapy
por: Ilander, Mette, et al.
Publicado: (2014)

IFN-α with dasatinib broadens the immune repertoire in patients with chronic-phase chronic myeloid leukemia
por: Huuhtanen, Jani, et al.
Publicado: (2022)

Dasatinib promotes Th1-type responses in granzyme B expressing T-cells
por: Kreutzman, Anna, et al.
Publicado: (2014)

Down-regulation of miR-181c in imatinib-resistant chronic myeloid leukemia
por: Mosakhani, Neda, et al.
Publicado: (2013)

STAT5b in LGL leukemia – a novel therapeutic target?
por: Rajala, Hanna L. M., et al.
Publicado: (2013)

Age-associated changes in the immune system may influence the response to anti-PD1 therapy in metastatic melanoma patients
por: Kasanen, Henna, et al.
Publicado: (2020)

Immune cell phenotype and functional defects in Netherton syndrome
por: Eränkö, Elina, et al.
Publicado: (2018)

Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity
por: Schiffer, Charles A., et al.
Publicado: (2016)

The transformative journey of chronic myeloid leukemia
por: Neelakantan, Pratap, et al.
Publicado: (2018)

Chronic myeloid leukemia versus acute myeloid leukemia in patients with retinoblastoma
por: Leahey, Ann-Marie, et al.
Publicado: (2021)

Chronic myeloid leukemia in India
por: Goldman, John M.
Publicado: (2013)

Will immune therapy cure acute myeloid leukemia?
por: Gale, Robert Peter
Publicado: (2019)

Increased Level of Myeloid-Derived Suppressor Cells, Programmed Death Receptor Ligand 1/Programmed Death Receptor 1, and Soluble CD25 in Sokal High Risk Chronic Myeloid Leukemia
por: Christiansson, Lisa, et al.
Publicado: (2013)

Imatinib in chronic myeloid leukemia elderly patients
por: Gugliotta, Gabriele, et al.
Publicado: (2011)

Chronic myeloid leukemia: An Indian scenario
por: Digumarti, Raghunadharao
Publicado: (2016)

What is treatment free remission in chronic myeloid leukemia?
por: Rea, Delphine, et al.
Publicado: (2017)

Chronic Myeloid Leukemia Prognosis and Therapy: Criticisms and Perspectives
por: Russo, Domenico, et al.
Publicado: (2020)

Early BCR-ABL1 Transcript Decline after 1 Month of Tyrosine Kinase Inhibitor Therapy as an Indicator for Treatment Response in Chronic Myeloid Leukemia
por: El Missiry, Mohamed, et al.
Publicado: (2017)

Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia
por: Ilander, M, et al.
Publicado: (2017)

T and NK cell abundance defines two distinct subgroups of renal cell carcinoma
por: Lee, Moon Hee, et al.
Publicado: (2022)

Single cell immune profiling by mass cytometry of newly diagnosed chronic phase chronic myeloid leukemia treated with nilotinib
por: Gullaksen, Stein-Erik, et al.
Publicado: (2017)

Tyrosine Kinase Inhibitor Sequencing in Patients with Chronic Myeloid Leukemia
por: Tiribelli, Mario, et al.
Publicado: (2019)

Chronic Myeloid Leukemia Patients in Prolonged Remission following Interferon-α Monotherapy Have Distinct Cytokine and Oligoclonal Lymphocyte Profile
por: Kreutzman, Anna, et al.
Publicado: (2011)

CD36 defines primitive chronic myeloid leukemia cells less responsive to imatinib but vulnerable to antibody-based therapeutic targeting
por: Landberg, Niklas, et al.
Publicado: (2018)

Epigenetic modifier gene mutations in chronic myeloid leukemia (CML) at diagnosis are associated with risk of relapse upon treatment discontinuation
por: Adnan Awad, Shady, et al.
Publicado: (2022)

Characterization of p190-Bcr-Abl chronic myeloid leukemia reveals specific signaling pathways and therapeutic targets
por: Adnan-Awad, Shady, et al.
Publicado: (2020)

Chronic myeloid leukemia in children, do we have all the answers?
por: Bansal, Shweta
Publicado: (2014)

Chronic myeloid leukemia: Review of our Indian experience
por: Bhave, Abhay A.
Publicado: (2013)

RUNX1 mutations in blast-phase chronic myeloid leukemia associate with distinct phenotypes, transcriptional profiles, and drug responses
por: Adnan Awad, Shady, et al.
Publicado: (2020)

Chronic Myeloid Leukemia in Children and Adolescents: The Achilles Heel of Oncogenesis and Tyrosine Kinase Inhibitors
por: Moschovi, Maria, et al.
Publicado: (2021)

New patterns of genetic instability in chronic myeloid leukemia: interesting, but not ready for clinical use
por: Schiffer, Charles A.
Publicado: (2023)

Targeting PR1 in myeloid leukemia
por: Alatrash, Gheath, et al.
Publicado: (2017)

Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors
por: Pietarinen, Paavo O., et al.
Publicado: (2017)

Fusion genes in acute myeloid leukemia: do acute myeloid leukemia diagnostics need to fuse with RNA-sequencing?
por: Thol, Felicitas
Publicado: (2022)

Chronic Myeloid Leukemia in Children: Immune Function and Vaccinations
por: Suttorp, Meinolf, et al.
Publicado: (2021)

Chronic myeloid leukemia
por: Hantschel, Oliver
Publicado: (2019)

Chronic myeloid leukemia
por: Sauβele, Susanne
Publicado: (2018)

A Critical History of Chromic Myeloid Leukemia
por: Baccarani, Michele, et al.
Publicado: (2014)

Differentiation and Cell Survival of Myeloid Leukemia Cells
por: Studzinski, George P., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_n10d5d255vpm9666g9mnrbrefu